Literature DB >> 3785485

Relationship between aldosterone and sodium, potassium, and uric acid clearance in cirrhosis with and without ascites.

G Decaux, B Hanson, P Cauchie, D Bosson, J Unger.   

Abstract

We have suggested that cirrhotic patients with high uric acid clearances had an increased effective vascular volume. This hypothesis was tested by studying the relationship between the excretion of uric acid, sodium, potassium, and aldosterone in cirrhosis. In 29 consecutive cirrhotic patients, of whom 17 had ascites, and in a control group, the logarithm of urinary sodium and aldosterone excretion highly correlated in control (r = -0.79, p less than 0.001) and cirrhotic patients without (r = -0.72, p less than 0.01) and with (r = -0.80, p less than 0.001) ascites. The regression line significantly shifted to the left in the cirrhotic patients (p less than 0.001). The urinary ratio K/K + Na also correlated with urinary aldosterone in controls (r = +0.66, p less than 0.001) and in cirrhotic patients (r = +0.77, p less than 0.001); this regression line shifted to the right in cirrhosis patients (p less than 0.02). The fractional uric acid excretion significantly correlated with urinary aldosterone only in cirrhotic patients (r = -0.76, p less than 0.001). These data confirmed the existence of hypoaldosteronism in many cirrhotic patients and are consistent with tubular hypersensitivity to aldosterone and emphasize the major role of the effective vascular volume in the control of urid acid clearance in cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3785485     DOI: 10.1159/000183991

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  2 in total

1.  Raised urea clearance in cirrhotic patients with high uric acid clearance is related to low salt excretion.

Authors:  G Decaux; F Prospert; B Namias; M Schlesser; A Soupart
Journal:  Gut       Date:  1992-08       Impact factor: 23.059

Review 2.  Do vasopressin V2 receptor antagonists benefit cirrhotics with refractory ascites?

Authors:  Hiroshi Fukui
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.